Core Viewpoint - Voyager Therapeutics, Inc. is a biotechnology company focused on developing genetic treatments for neurological diseases, with a strong emphasis on innovative therapies and a promising financial outlook despite a negative EPS [1][6] Financial Performance - For the quarter ending March 9, 2026, Voyager reported an EPS of -$0.46, which was below the estimated -$0.40, but the revenue of $15.34 million exceeded the estimated $10 million by 57.97% and showed significant growth from $6.28 million in the same quarter last year [2][6] - The quarterly loss of $0.46 per share was better than the Zacks Consensus Estimate of a $0.54 loss, resulting in a positive surprise of 15.08% [3][6] Financial Health - Voyager has a strong cash position of $202 million, which is expected to sustain operations until 2028, and a low debt-to-equity ratio of 0.19, indicating a relatively low level of debt compared to equity [4][6] - The company has a robust current ratio of 7.64, suggesting a strong ability to cover short-term liabilities with short-term assets [4] Valuation Metrics - Voyager's price-to-earnings (P/E) ratio is approximately -2.01, reflecting negative earnings, while the price-to-sales ratio is about 5.66 and the enterprise value to sales ratio is approximately 4.95 [5]